aspc- 1 cell line Search Results


aspc1 cell line  (ATCC)
99
ATCC aspc1 cell line
Figure 1. Surface expression of DR5 and TRAIL sensitivity of Jurkat and pancreatic cancer cells. FACS data demonstrate surface expression of DR5 on Jurkat (a), <t>AsPC1(b)</t> and Panc1 (c) cells. Cells were incubated with the APC-conjugated anti-DR5 antibody and analyzed by flow cytometry. The red line indicates cells labeled with anti-DR5 antibody and black line for unlabeled cells. (d) TRAIL sensitivity of AsPC1, Panc1 and Jurkat cancer cells. Caspase-8 activity was measured in Jurkat, and pancreatic cancer cells treated with increasing concentrations of TRAIL (0.000001–10 μg/ml). Data are presented as mean ± standard deviation (N = 3).
Aspc1 Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aspc-+1+cell+line/AsPC-1/pm36775838-22-2-16
Average 99 stars, based on 1 article reviews
aspc1 cell line - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier

Image Search Results


Figure 1. Surface expression of DR5 and TRAIL sensitivity of Jurkat and pancreatic cancer cells. FACS data demonstrate surface expression of DR5 on Jurkat (a), AsPC1(b) and Panc1 (c) cells. Cells were incubated with the APC-conjugated anti-DR5 antibody and analyzed by flow cytometry. The red line indicates cells labeled with anti-DR5 antibody and black line for unlabeled cells. (d) TRAIL sensitivity of AsPC1, Panc1 and Jurkat cancer cells. Caspase-8 activity was measured in Jurkat, and pancreatic cancer cells treated with increasing concentrations of TRAIL (0.000001–10 μg/ml). Data are presented as mean ± standard deviation (N = 3).

Journal: Cancer biology & therapy

Article Title: Nimesulide, a COX-2 inhibitor, sensitizes pancreatic cancer cells to TRAIL-induced apoptosis by promoting DR5 clustering †.

doi: 10.1080/15384047.2023.2176692

Figure Lengend Snippet: Figure 1. Surface expression of DR5 and TRAIL sensitivity of Jurkat and pancreatic cancer cells. FACS data demonstrate surface expression of DR5 on Jurkat (a), AsPC1(b) and Panc1 (c) cells. Cells were incubated with the APC-conjugated anti-DR5 antibody and analyzed by flow cytometry. The red line indicates cells labeled with anti-DR5 antibody and black line for unlabeled cells. (d) TRAIL sensitivity of AsPC1, Panc1 and Jurkat cancer cells. Caspase-8 activity was measured in Jurkat, and pancreatic cancer cells treated with increasing concentrations of TRAIL (0.000001–10 μg/ml). Data are presented as mean ± standard deviation (N = 3).

Article Snippet: Jurkat and AsPC1 cell line were cultured in RPMI 1640 with HEPES, sodium pyruvate, and L-glutamine (ATCC).

Techniques: Expressing, Incubation, Flow Cytometry, Labeling, Activity Assay, Standard Deviation

Figure 3. Effect of nimesulide on caspase-8 activity in AsPC1 and Panc1 cancer cells. Caspase-8 activity was measured in AsPC1 (a) and Panc1 (b) cancer cells treated with increasing concentrations of nimesulide-only (0.001–200 μM). (c) AspC1 cells treated with increasing concentrations of TRAIL (0.000001–10 μg/ml) +DMSO or TRAIL+nimesulide (50 μM). (d) PanC1 cells treated with increasing concentrations of TRAIL (0.000001–10 μg/ml) +DMSO or TRAIL+nimesulide (50 μM). Data are presented as mean ± standard deviation (N = 3).

Journal: Cancer biology & therapy

Article Title: Nimesulide, a COX-2 inhibitor, sensitizes pancreatic cancer cells to TRAIL-induced apoptosis by promoting DR5 clustering †.

doi: 10.1080/15384047.2023.2176692

Figure Lengend Snippet: Figure 3. Effect of nimesulide on caspase-8 activity in AsPC1 and Panc1 cancer cells. Caspase-8 activity was measured in AsPC1 (a) and Panc1 (b) cancer cells treated with increasing concentrations of nimesulide-only (0.001–200 μM). (c) AspC1 cells treated with increasing concentrations of TRAIL (0.000001–10 μg/ml) +DMSO or TRAIL+nimesulide (50 μM). (d) PanC1 cells treated with increasing concentrations of TRAIL (0.000001–10 μg/ml) +DMSO or TRAIL+nimesulide (50 μM). Data are presented as mean ± standard deviation (N = 3).

Article Snippet: Jurkat and AsPC1 cell line were cultured in RPMI 1640 with HEPES, sodium pyruvate, and L-glutamine (ATCC).

Techniques: Activity Assay, Standard Deviation

Figure 4. Effect of nimesulide on TRAIL-induced apoptosis in pancreatic cancer cells and proliferation of all three cancer cells. Apoptosis was measured using MTT assay in AsPC1 (a) and Panc1 (b). Cancer cells were treated with increasing concentrations of TRAIL (0.000001–10 μg/ml) +DMSO or TRAIL+nimesulide (50 μM). Data are presented as mean ± standard deviation (N = 3). AsPC1 (c), Panc1 (d) and Jurkat (e) cells were treated separately with DMSO or nimesulide (0.001–200 μM) and incubated for 24 hours and cell proliferation was measured using MTT assay. Data are mean ± SD (N = 3).

Journal: Cancer biology & therapy

Article Title: Nimesulide, a COX-2 inhibitor, sensitizes pancreatic cancer cells to TRAIL-induced apoptosis by promoting DR5 clustering †.

doi: 10.1080/15384047.2023.2176692

Figure Lengend Snippet: Figure 4. Effect of nimesulide on TRAIL-induced apoptosis in pancreatic cancer cells and proliferation of all three cancer cells. Apoptosis was measured using MTT assay in AsPC1 (a) and Panc1 (b). Cancer cells were treated with increasing concentrations of TRAIL (0.000001–10 μg/ml) +DMSO or TRAIL+nimesulide (50 μM). Data are presented as mean ± standard deviation (N = 3). AsPC1 (c), Panc1 (d) and Jurkat (e) cells were treated separately with DMSO or nimesulide (0.001–200 μM) and incubated for 24 hours and cell proliferation was measured using MTT assay. Data are mean ± SD (N = 3).

Article Snippet: Jurkat and AsPC1 cell line were cultured in RPMI 1640 with HEPES, sodium pyruvate, and L-glutamine (ATCC).

Techniques: MTT Assay, Standard Deviation, Incubation

Figure 8. Effect of nimesulide on DR5 expression. FACS data demonstrate surface expression of DR5 on AsPC1 (a) or Panc1 (b) cells. Cells were treated separately with DMSO or nimesulide and incubated for 24 hours. After incubation cells were washed with PBS and incubated with APC-conjugated anti-DR5 antibody and analyzed by flow cytometry. The black line indicates for unlabeled cells, green for cells treated with DMSO and Orange (50 μM) and magenta (100 μM) for cells treated with nimesulide. (c) Cancer cells were treated with or without nimesulide (50 μM) and incubated for 24 hours. After incubation cells were washed with PBS and lysed with native lysis buffer. Equal amounts of total protein were loaded and resolved by 4–20% Tris-glycine SDS−PAGE gels and immunoblotted with antibodies against DR5 and β-Actin.

Journal: Cancer biology & therapy

Article Title: Nimesulide, a COX-2 inhibitor, sensitizes pancreatic cancer cells to TRAIL-induced apoptosis by promoting DR5 clustering †.

doi: 10.1080/15384047.2023.2176692

Figure Lengend Snippet: Figure 8. Effect of nimesulide on DR5 expression. FACS data demonstrate surface expression of DR5 on AsPC1 (a) or Panc1 (b) cells. Cells were treated separately with DMSO or nimesulide and incubated for 24 hours. After incubation cells were washed with PBS and incubated with APC-conjugated anti-DR5 antibody and analyzed by flow cytometry. The black line indicates for unlabeled cells, green for cells treated with DMSO and Orange (50 μM) and magenta (100 μM) for cells treated with nimesulide. (c) Cancer cells were treated with or without nimesulide (50 μM) and incubated for 24 hours. After incubation cells were washed with PBS and lysed with native lysis buffer. Equal amounts of total protein were loaded and resolved by 4–20% Tris-glycine SDS−PAGE gels and immunoblotted with antibodies against DR5 and β-Actin.

Article Snippet: Jurkat and AsPC1 cell line were cultured in RPMI 1640 with HEPES, sodium pyruvate, and L-glutamine (ATCC).

Techniques: Expressing, Incubation, Flow Cytometry, Lysis, SDS Page